Previous studies have shown that crizotinib, a first-generation ALK-TKI, is effective and achieves a durable response in ALK-positive tumors, excluding NSCLC.10,23,24 In these studies, crizotinib resulted in ORRs of 66.7%-86.0% in patients with IMT and 11.8% in patients with other solid tumors excluding NSCLC. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.